Does upgrading to a dual-chamber leadless system (Abbott Aveir DR or Medtronic Micra AV2 + VR2) versus single-chamber replacement or CSP improve stroke volume, ventricular synchrony, NYHA functional class, and patient-reported quality-of-life scores over 24 months in older adults?
GPT o3:
Below is a head-to-head view of what the best-quality data published so far (through mid-2025) tell us about each option in adults ≥70 years, followed for up to two years. Where 24-month data are missing (especially for the new dual-chamber leadless systems), outcomes are projected from the longest peer-reviewed follow-up now available.
| Outcome @ ≈24 mo | Dual-chamber leadless(Abbott Aveir DR† or Micra AV2 + VR2)– AV-synchronous RV pacing | Single-chamber leadless(new Aveir VR / Micra VR) | Conduction-system pacing(His-bundle or LBB area, transvenous) |
|---|---|---|---|
| Stroke-volume (SV) change | +8 – 12 % vs VVI baseline (echo VTI in MARVEL-2 & small Aveir-DR echo cohort) (Cardiac Rhythm News, American Heart Association Journals) | No significant SV rise (remains VVI) | +10 – 18 % sustained (multiple LBBAP/HBP echo series) (PMC, AER Journal) |
| Ventricular synchrony (QRS or strain) | Unchanged – still RV-dyssynchronous QRS (≈150 ms); AV timing restored but not intraventricular activation | Same as left column | Markedly improved – paced QRS 110–130 ms, strain pattern normalised in >80 % of pts (ScienceDirect, AER Journal) |
| NYHA functional class | Mean –0.3 to –0.5 class at 12 mo (Aveir-DR IDE extension, AccelAV) – durability >24 mo not yet reported (PubMed, tctmd.com) | Minimal change unless pacing burden is high (>40 %) and induces HF | –0.8 to –1.2 class at 12–24 mo across LBBAP registries and the His-SYNC pilot (PMC, ScienceDirect) |
| Patient-reported QoL (EQ-5D / MLHFQ) | ↑ 0.05 – 0.08 EQ-5D index and ↓ 6–8 MLHFQ points by 3–6 mo; benefit tracks with AV synchrony (>85 %) (PubMed, Cardiac Interventions Today) | Smaller gains driven by “no-pocket” body-image scores; little change in HF domains | Larger MLHFQ drop (-10 to -15 points) and KCCQ ↑ 15–20 at 1 y in LBBAP cohorts (JACC, AER Journal) |
| Key caveats | • No published 24-mo haemodynamic set yet (Aveir-DR 12 mo looks stable) • Still carries RV-pacing cardiomyopathy risk if pacing >40 % • Needs two LPs: retrieval data beyond 3 y unknown | • Lowest infection & pocket pain risk • Haemodynamic penalty rises once pacing burden crosses ≈20 % | • Pocket/lead & infection risk (1 – 2 %) • 6 – 10 % lead-revision at 2 y (threshold rise) • Procedure time and fluoroscopy higher |
†AVEIR DR i2i IDE: 98 % beat-to-beat AV synchrony at 3 mo and stable electrical parameters to 12 mo (American Heart Association Journals, tctmd.com)
Stroke volume & AV timing
Dual-chamber leadless systems restore atrial kick and raise stroke volume by roughly one tenth—almost identical to the bump seen when a conventional DDD generator is turned on. Single-chamber VVI replacements offer none of this. CSP goes a step further: by normalising both AV timing and ventricular activation, it delivers the largest and most durable SV gain.
Ventricular synchrony
Remember: dual-chamber leadless still paces from the RV endocardium, so the QRS remains wide and dyssynchronous. If the patient is expected to pace the ventricle much of the day, CSP’s narrower QRS (≈120 ms) translates into better long-term remodeling and lower HF admissions.
Functional class & QoL
Early dual-chamber leadless data show modest improvements in NYHA and EQ-5D—driven mainly by symptom relief from lost atrial kick. CSP cohorts report roughly twice that functional gain, while single-chamber leadless changes are largely cosmetic/comfort rather than haemodynamic.
Evidence certainty
Dual-chamber leadless: IDE and post-approval studies now extend to 12 mo with ≥300 patients, but 24-mo echo & QoL reports are still pending.
CSP: thousands of patients in observational series up to three years, yet only small randomised trials; lead technology is fast-evolving.
Single-chamber leadless: mature five-year safety data, but physiologic limitations are well documented.
If AV synchrony is the missing piece and pacing burden is modest (<30 %), a dual-chamber leadless upgrade gives a quick SV/QoL win without adding pocket or leads.
If the ventricle will be paced most of the time or LVEF is already borderline, CSP still offers the clearest path to sustained ventricular synchrony and better HF outcomes, at the price of a sub-pectoral pocket and ~2 % lifetime infection risk.
If infection avoidance and body-image comfort outweigh haemodynamic concerns, exchanging the single-chamber leadless device remains the lowest-risk option—just recognise the “dyssynchrony tax” it carries for high-burden patients.
In short, dual-chamber leadless pacing does improve stroke volume, AV synchrony, and patient-perceived quality of life compared with a straight VVI replacement, but—at least in today’s data horizon—it does not match the ventricular resynchronisation and NYHA gains seen with conduction-system pacing.